Global Biosimilars and Innovative Biological Drugs Market Outlook , 2030
Due to strict international quality, safety, and effectiveness regulations, the worldwide biosimilars and innovative biologics market is expected to reach a valuation of over $713
- Bonafide Trust
- 03-07-2024
- Pages : 130
- Figures : 78
- Tables : 147
- Region : Global
- Category : Lifescience & Healthcare
- Pharmaceutical
The global biosimilars and innovative biological drugs market represents a dynamic intersection of biotechnology, healthcare, and regulatory landscapes. Biosimilars, as biotherapeutic counterparts to original biologic drugs, have emerged as a critical component of healthcare systems, offering cost-effective alternatives while maintaining therapeutic efficacy. On the other hand, innovative biological drugs continue to push the boundaries of medical science, addressing complex diseases and unmet medical needs. This intricate interplay between biosimilars and innovative biologics shapes the overall Market Dynamics, influencing treatment paradigms, healthcare expenditure, and patient access. The global biosimilars and innovative biological drugs market exhibits distinct characteristics across different therapeutic areas. Oncology, immunology, and rheumatology are major segments driving market growth, with a pipeline of innovative biologics and biosimilars in development. The complexity of manufacturing and characterizing biological drugs poses significant challenges, requiring specialized expertise and advanced technologies. Regulatory approval processes for both biosimilars and innovative biologics are rigorous, involving extensive clinical trials and safety assessments. Intellectual property rights and patent protection are critical considerations for pharmaceutical companies, influencing market competition and product lifecycle management. Moreover, the reimbursement landscape varies across countries, impacting drug accessibility and affordability.
According to the research report, “Global Biosimilars and Innovative Biological Drugs Market Outlook, 2030” published by Bonafide Research, the market is anticipated to cross USD 713020 million by 2030 increasing from USD US$ 424560 million in 2024. Stringent quality, safety, and efficacy standards are imposed by regulatory authorities worldwide to ensure patient safety and product efficacy. Biosimilars, while similar to their reference products, undergo rigorous approval processes to demonstrate comparability. Innovative biological drugs face their own set of regulatory hurdles, including clinical trial requirements and market authorization procedures. The regulatory landscape varies across countries, impacting market entry strategies and product lifecycle management. Opportunities for growth in the biosimilars and innovative biological drugs market are driven by factors such as increasing prevalence of chronic diseases, aging populations, and rising healthcare expenditures. International conferences, symposia, and trade shows serve as platforms for knowledge exchange, networking, and business development. However, the market is also characterized by intense competition, with pharmaceutical companies investing heavily in research and development to create innovative products and protect their intellectual property. Pricing and reimbursement strategies are critical determinants of market success for both biosimilars and innovative biological drugs. Biosimilars are typically priced lower than their reference products, leveraging cost-saving advantages. However, achieving price parity and securing favorable reimbursement policies can be challenging. Innovative biological drugs often command premium prices due to their therapeutic value and the high costs associated with research and development. However, pricing pressures and the need for cost-effective healthcare solutions are influencing pricing strategies. The global economy, measured by purchasing power parity (PPP), influences the biosimilars and innovative biological drugs market. Countries with higher per capita income generally have greater healthcare spending, leading to higher demand for these products. However, access to these medicines can be limited in lower-income countries due to affordability concerns.
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Dynamics
Market Drivers
Growing Prevalence of Chronic Diseases: The increasing incidence of chronic diseases, such as cancer, autoimmune disorders, and diabetes, is driving demand for both innovative biologics and biosimilars. These diseases often require long-term treatment, creating a substantial market for therapeutic options. As the global population ages, the burden of chronic diseases is expected to rise, further fueling market growth.
Increasing Healthcare Spending: Rising healthcare expenditures, particularly in developed economies, are supporting investments in research and development for novel biologics. The potential for significant returns on investment is encouraging pharmaceutical companies to allocate resources to this area. Additionally, the growing middle class in emerging markets is expanding access to healthcare, creating new opportunities for both innovative biologics and biosimilars.
Favorable Regulatory Environment: Supportive regulatory frameworks are accelerating the development and commercialization of biosimilars and innovative biologics. Clear guidelines and streamlined approval processes are essential for bringing new therapies to market efficiently. Many countries have implemented policies to promote biosimilar adoption, further stimulating market growth.
Market Challenges
• Complex Development and Manufacturing Processes: Developing and manufacturing biologics is inherently complex and costly compared to traditional small molecule drugs. The intricate nature of biological molecules presents significant challenges in terms of production, quality control, and analytical testing. Overcoming these hurdles requires substantial investments in research and development, as well as advanced manufacturing capabilities.
•
• Intellectual Property and Patent Disputes: The biopharmaceutical industry is characterized by intense intellectual property (IP) protection. Patent disputes and challenges can significantly delay market entry for both innovative biologics and biosimilars. Navigating the complex IP landscape is crucial for companies operating in this space.
•
• Patient Acceptance and Physician Education: Gaining patient and physician acceptance for biosimilars can be challenging due to concerns about efficacy and safety. Educating healthcare providers and patients about the benefits of biosimilars is essential for successful market adoption. Building trust and demonstrating interchangeability with originator biologics are key factors in overcoming these challenges.
Market Trends
Increasing Focus on Biosimilars and Biobetters: A growing emphasis on cost-effective healthcare solutions is driving a surge in the development and adoption of biosimilars. As patent cliffs for blockbuster biologics approach, biosimilars are emerging as viable alternatives, offering similar efficacy at lower costs. Additionally, there's a rising interest in biobetters, which are improved versions of existing biologics with enhanced therapeutic benefits, driving innovation in the market.
Advancements in Biotechnology and Manufacturing: Rapid advancements in biotechnology are fueling the development of complex and innovative biological drugs. These breakthroughs are expanding the therapeutic landscape, addressing previously unmet medical needs, and creating new market opportunities. Furthermore, improvements in manufacturing processes and technologies are enhancing production efficiency and reducing costs, making biological drugs more accessible.
Personalized Medicine and Targeted Therapies: The shift towards personalized medicine is reshaping the biopharmaceuticals market. Biologics are at the forefront of this trend, with tailored treatments emerging for specific patient populations. This focus on precision medicine is driving the development of companion diagnostics and biomarker-driven drug development, leading to more effective and targeted therapies.
•
Segmentation Analysis
Monoclonal Antibodies lead in the Global Biosimilars and Innovative Biological Drugs Market due to their versatility and effectiveness in treating a wide range of diseases.
The global biosimilars and innovative biological drugs market is significantly segmented by product type, with monoclonal antibodies (mAbs) emerging as the leading segment. This predominance is attributed to the substantial growth in the therapeutic applications of mAbs across various disease areas such as oncology, immunology, and infectious diseases. The complex structure and manufacturing processes associated with mAbs have traditionally presented significant challenges for biosimilar development, contributing to their higher pricing and market dominance. However, advancements in biosimilar development technologies have facilitated the entry of biosimilar mAbs into the market, intensifying competition and driving down costs. While interferons, insulin, and vaccines hold substantial market shares, their relatively simpler molecular structures compared to mAbs have allowed for earlier biosimilar development and broader market penetration. The 'others' category encompasses a diverse range of biological drugs, including growth hormones, erythropoietins, and coagulation factors, which contribute to the overall market but lack the same level of prominence as the aforementioned segments. The electronics industry leads in the Flip Chip market due to the increasing demand for smaller, faster, and more power-efficient electronic devices.
Hospitals lead in the Global Biosimilars and Innovative Biological Drugs Market due to their role as primary healthcare providers and the high volume of patients requiring these treatments.
The application of biosimilars and innovative biological drugs spans across various healthcare settings, with hospitals emerging as the dominant segment. Hospitals, as centers of specialized care and complex treatments, are early adopters of these advanced therapies due to their expertise in managing intricate drug administration and patient monitoring. These institutions often house specialized units like oncology, rheumatology, and immunology, where biologics are extensively used. Additionally, hospitals are equipped with the necessary infrastructure to handle the cold chain requirements of these drugs, ensuring their efficacy. The hospital segment is further influenced by factors such as reimbursement policies, drug formularies, and physician prescribing patterns. Hospitals frequently engage in cost-benefit analyses to evaluate the economic implications of adopting biosimilars, considering factors like drug acquisition costs, administration expenses, and potential savings from reduced length of stay. Moreover, the growing trend of hospital pharmacy centralization has streamlined the procurement and distribution of biologics, enhancing efficiency and cost-effectiveness. While retail pharmacies are gaining prominence in the distribution of certain biologics, hospitals remain the cornerstone of the application segment, driving innovation and shaping the overall Market Dynamics.
Regional Analysis
Europe leads in the Flip Chip market due to its strong foundation in pharmaceutical innovation, coupled with its focus on patient access and affordability.
Europe has established itself as a leading region in the global biosimilars and innovative biological drugs market, driven by a confluence of factors. The region boasts a strong pharmaceutical industry with a deep-rooted history of innovation and research excellence. This legacy has fostered a favorable environment for the development and commercialization of both biosimilars and innovative biological drugs. Additionally, Europe's comprehensive regulatory frameworks, such as those established by the European Medicines Agency (EMA), have played a pivotal role in ensuring the safety, efficacy, and quality of these products. These robust regulatory standards have instilled confidence in healthcare professionals and patients alike, driving the adoption of biosimilars and innovative biological drugs. Furthermore, Europe's healthcare systems, characterized by a mix of public and private insurance models, have created a conducive environment for the introduction of biosimilars as cost-saving alternatives to branded biologics. The region's emphasis on healthcare access and affordability has encouraged the development of policies and reimbursement mechanisms that support the adoption of biosimilars. This has led to a more competitive market landscape, benefiting patients and healthcare providers. Moreover, Europe's investment in research and development (R&D) for biosimilars and innovative biological drugs has been substantial. A strong ecosystem of academic institutions, research organizations, and biotechnology companies has contributed to the region's scientific advancements. This investment in R&D has not only fueled the development of new products but has also fostered a culture of innovation and collaboration within the European pharmaceutical industry. In addition to these factors, Europe's geographical proximity to other regions, such as North America and Asia-Pacific, has facilitated trade and knowledge exchange. The region's strong pharmaceutical industry has established partnerships and collaborations with global players, enabling the efficient dissemination of technology and expertise. This interconnectedness has contributed to Europe's position as a global leader in the biosimilars and innovative biological drugs market.
Key Developments
In August 2024, the FDA approved Sandoz's Enzeevu, the fourth biosimilar referencing Eylea. This biosimilar is used to treat neovascular age-related macular degeneration (nAMD) and was granted interchangeability, allowing for substitution at the pharmacy level without a doctor's visit. This approval is a significant milestone for increasing access to treatment for patients with nAMD, a leading cause of vision loss in people over 50.
Table of Contents
- 1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats
- 2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Biosimilars and Innovative Biological Drugs Market Size 2019-2030
- 2.1.2 Biosimilars and Innovative Biological Drugs Market Size CAGR by Region (2019 VS 2023 VS 2030)
- 2.1.3 World Current & Future Analysis for Biosimilars and Innovative Biological Drugs by Country/Region, 2019, 2023 & 2030
- 2.2 Biosimilars and Innovative Biological Drugs Segment by Type
- 2.2.1 Monoclonal Antibodies
- 2.2.2 Interferon
- 2.2.3 Insulin
- 2.2.4 Vaccines
- 2.2.5 Others
- 2.3 Biosimilars and Innovative Biological Drugs Market Size by Type
- 2.3.1 Biosimilars and Innovative Biological Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030)
- 2.3.2 Global Biosimilars and Innovative Biological Drugs Market Size Market Share by Type (2019-2024)
- 2.4 Biosimilars and Innovative Biological Drugs Segment by Application
- 2.4.1 Hospital
- 2.4.2 Retail Pharmacy
- 2.4.3 Other
- 2.5 Biosimilars and Innovative Biological Drugs Market Size by Application
- 2.5.1 Biosimilars and Innovative Biological Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030)
- 2.5.2 Global Biosimilars and Innovative Biological Drugs Market Size Market Share by Application (2019-2024)
- 3 Biosimilars and Innovative Biological Drugs Market Size by Player
- 3.1 Biosimilars and Innovative Biological Drugs Market Size Market Share by Player
- 3.1.1 Global Biosimilars and Innovative Biological Drugs Revenue by Player (2019-2024)
- 3.1.2 Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Player (2019-2024)
- 3.2 Global Biosimilars and Innovative Biological Drugs Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
- 4 Biosimilars and Innovative Biological Drugs by Region
- 4.1 Biosimilars and Innovative Biological Drugs Market Size by Region (2019-2024)
- 4.2 Global Biosimilars and Innovative Biological Drugs Annual Revenue by Country/Region (2019-2024)
- 4.3 Americas Biosimilars and Innovative Biological Drugs Market Size Growth (2019-2024)
- 4.4 APAC Biosimilars and Innovative Biological Drugs Market Size Growth (2019-2024)
- 4.5 Europe Biosimilars and Innovative Biological Drugs Market Size Growth (2019-2024)
- 4.6 Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size Growth (2019-2024)
- 5 Americas
- 5.1 Americas Biosimilars and Innovative Biological Drugs Market Size by Country (2019-2024)
- 5.2 Americas Biosimilars and Innovative Biological Drugs Market Size by Type (2019-2024)
- 5.3 Americas Biosimilars and Innovative Biological Drugs Market Size by Application (2019-2024)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
- 6 APAC
- 6.1 APAC Biosimilars and Innovative Biological Drugs Market Size by Region (2019-2024)
- 6.2 APAC Biosimilars and Innovative Biological Drugs Market Size by Type (2019-2024)
- 6.3 APAC Biosimilars and Innovative Biological Drugs Market Size by Application (2019-2024)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 7 Europe
- 7.1 Europe Biosimilars and Innovative Biological Drugs Market Size by Country (2019-2024)
- 7.2 Europe Biosimilars and Innovative Biological Drugs Market Size by Type (2019-2024)
- 7.3 Europe Biosimilars and Innovative Biological Drugs Market Size by Application (2019-2024)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 8 Middle East & Africa
- 8.1 Middle East & Africa Biosimilars and Innovative Biological Drugs by Region (2019-2024)
- 8.2 Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size by Type (2019-2024)
- 8.3 Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size by Application (2019-2024)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
- 9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
- 10 Global Biosimilars and Innovative Biological Drugs Market Forecast
- 10.1 Global Biosimilars and Innovative Biological Drugs Forecast by Region (2025-2030)
- 10.1.1 Global Biosimilars and Innovative Biological Drugs Forecast by Region (2025-2030)
- 10.1.2 Americas Biosimilars and Innovative Biological Drugs Forecast
- 10.1.3 APAC Biosimilars and Innovative Biological Drugs Forecast
- 10.1.4 Europe Biosimilars and Innovative Biological Drugs Forecast
- 10.1.5 Middle East & Africa Biosimilars and Innovative Biological Drugs Forecast
- 10.2 Americas Biosimilars and Innovative Biological Drugs Forecast by Country (2025-2030)
- 10.2.1 United States Market Biosimilars and Innovative Biological Drugs Forecast
- 10.2.2 Canada Market Biosimilars and Innovative Biological Drugs Forecast
- 10.2.3 Mexico Market Biosimilars and Innovative Biological Drugs Forecast
- 10.2.4 Brazil Market Biosimilars and Innovative Biological Drugs Forecast
- 10.3 APAC Biosimilars and Innovative Biological Drugs Forecast by Region (2025-2030)
- 10.3.1 China Biosimilars and Innovative Biological Drugs Market Forecast
- 10.3.2 Japan Market Biosimilars and Innovative Biological Drugs Forecast
- 10.3.3 Korea Market Biosimilars and Innovative Biological Drugs Forecast
- 10.3.4 Southeast Asia Market Biosimilars and Innovative Biological Drugs Forecast
- 10.3.5 India Market Biosimilars and Innovative Biological Drugs Forecast
- 10.3.6 Australia Market Biosimilars and Innovative Biological Drugs Forecast
- 10.4 Europe Biosimilars and Innovative Biological Drugs Forecast by Country (2025-2030)
- 10.4.1 Germany Market Biosimilars and Innovative Biological Drugs Forecast
- 10.4.2 France Market Biosimilars and Innovative Biological Drugs Forecast
- 10.4.3 UK Market Biosimilars and Innovative Biological Drugs Forecast
- 10.4.4 Italy Market Biosimilars and Innovative Biological Drugs Forecast
- 10.4.5 Russia Market Biosimilars and Innovative Biological Drugs Forecast
- 10.5 Middle East & Africa Biosimilars and Innovative Biological Drugs Forecast by Region (2025-2030)
- 10.5.1 Egypt Market Biosimilars and Innovative Biological Drugs Forecast
- 10.5.2 South Africa Market Biosimilars and Innovative Biological Drugs Forecast
- 10.5.3 Israel Market Biosimilars and Innovative Biological Drugs Forecast
- 10.5.4 Turkey Market Biosimilars and Innovative Biological Drugs Forecast
- 10.6 Global Biosimilars and Innovative Biological Drugs Forecast by Type (2025-2030)
- 10.7 Global Biosimilars and Innovative Biological Drugs Forecast by Application (2025-2030)
- 10.7.1 GCC Countries Market Biosimilars and Innovative Biological Drugs Forecast
- 11 Key Players Analysis
- 11.1 Roche
- 11.1.1 Roche Company Information
- 11.1.2 Roche Biosimilars and Innovative Biological Drugs Product Offered
- 11.1.3 Roche Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.1.4 Roche Main Business Overview
- 11.1.5 Roche Latest Developments
- 11.2 Amgen
- 11.2.1 Amgen Company Information
- 11.2.2 Amgen Biosimilars and Innovative Biological Drugs Product Offered
- 11.2.3 Amgen Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.2.4 Amgen Main Business Overview
- 11.2.5 Amgen Latest Developments
- 11.3 AbbVie
- 11.3.1 AbbVie Company Information
- 11.3.2 AbbVie Biosimilars and Innovative Biological Drugs Product Offered
- 11.3.3 AbbVie Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.3.4 AbbVie Main Business Overview
- 11.3.5 AbbVie Latest Developments
- 11.4 Sanofi
- 11.4.1 Sanofi Company Information
- 11.4.2 Sanofi Biosimilars and Innovative Biological Drugs Product Offered
- 11.4.3 Sanofi Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.4.4 Sanofi Main Business Overview
- 11.4.5 Sanofi Latest Developments
- 11.5 Johnson & Johnson
- 11.5.1 Johnson & Johnson Company Information
- 11.5.2 Johnson & Johnson Biosimilars and Innovative Biological Drugs Product Offered
- 11.5.3 Johnson & Johnson Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.5.4 Johnson & Johnson Main Business Overview
- 11.5.5 Johnson & Johnson Latest Developments
- 11.6 Pfizer
- 11.6.1 Pfizer Company Information
- 11.6.2 Pfizer Biosimilars and Innovative Biological Drugs Product Offered
- 11.6.3 Pfizer Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.6.4 Pfizer Main Business Overview
- 11.6.5 Pfizer Latest Developments
- 11.7 Novo Nordisk
- 11.7.1 Novo Nordisk Company Information
- 11.7.2 Novo Nordisk Biosimilars and Innovative Biological Drugs Product Offered
- 11.7.3 Novo Nordisk Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.7.4 Novo Nordisk Main Business Overview
- 11.7.5 Novo Nordisk Latest Developments
- 11.8 Eli Lilly
- 11.8.1 Eli Lilly Company Information
- 11.8.2 Eli Lilly Biosimilars and Innovative Biological Drugs Product Offered
- 11.8.3 Eli Lilly Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.8.4 Eli Lilly Main Business Overview
- 11.8.5 Eli Lilly Latest Developments
- 11.9 Novartis
- 11.9.1 Novartis Company Information
- 11.9.2 Novartis Biosimilars and Innovative Biological Drugs Product Offered
- 11.9.3 Novartis Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.9.4 Novartis Main Business Overview
- 11.9.5 Novartis Latest Developments
- 11.10 Merck
- 11.10.1 Merck Company Information
- 11.10.2 Merck Biosimilars and Innovative Biological Drugs Product Offered
- 11.10.3 Merck Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.10.4 Merck Main Business Overview
- 11.10.5 Merck Latest Developments
- 11.11 Biogen
- 11.11.1 Biogen Company Information
- 11.11.2 Biogen Biosimilars and Innovative Biological Drugs Product Offered
- 11.11.3 Biogen Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.11.4 Biogen Main Business Overview
- 11.11.5 Biogen Latest Developments
- 11.12 Celltrion
- 11.12.1 Celltrion Company Information
- 11.12.2 Celltrion Biosimilars and Innovative Biological Drugs Product Offered
- 11.12.3 Celltrion Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.12.4 Celltrion Main Business Overview
- 11.12.5 Celltrion Latest Developments
- 11.13 Sobi
- 11.13.1 Sobi Company Information
- 11.13.2 Sobi Biosimilars and Innovative Biological Drugs Product Offered
- 11.13.3 Sobi Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.13.4 Sobi Main Business Overview
- 11.13.5 Sobi Latest Developments
- 11.14 3SBIO
- 11.14.1 3SBIO Company Information
- 11.14.2 3SBIO Biosimilars and Innovative Biological Drugs Product Offered
- 11.14.3 3SBIO Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.14.4 3SBIO Main Business Overview
- 11.14.5 3SBIO Latest Developments
- 11.15 Changchun High Tech
- 11.15.1 Changchun High Tech Company Information
- 11.15.2 Changchun High Tech Biosimilars and Innovative Biological Drugs Product Offered
- 11.15.3 Changchun High Tech Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.15.4 Changchun High Tech Main Business Overview
- 11.15.5 Changchun High Tech Latest Developments
- 11.16 Kanghong Pharma
- 11.16.1 Kanghong Pharma Company Information
- 11.16.2 Kanghong Pharma Biosimilars and Innovative Biological Drugs Product Offered
- 11.16.3 Kanghong Pharma Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.16.4 Kanghong Pharma Main Business Overview
- 11.16.5 Kanghong Pharma Latest Developments
- 11.17 Innovent Biologics
- 11.17.1 Innovent Biologics Company Information
- 11.17.2 Innovent Biologics Biosimilars and Innovative Biological Drugs Product Offered
- 11.17.3 Innovent Biologics Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.17.4 Innovent Biologics Main Business Overview
- 11.17.5 Innovent Biologics Latest Developments
- 11.18 Gan&Lee
- 11.18.1 Gan&Lee Company Information
- 11.18.2 Gan&Lee Biosimilars and Innovative Biological Drugs Product Offered
- 11.18.3 Gan&Lee Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.18.4 Gan&Lee Main Business Overview
- 11.18.5 Gan&Lee Latest Developments
- 11.19 Tonghua Dongbao
- 11.19.1 Tonghua Dongbao Company Information
- 11.19.2 Tonghua Dongbao Biosimilars and Innovative Biological Drugs Product Offered
- 11.19.3 Tonghua Dongbao Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.19.4 Tonghua Dongbao Main Business Overview
- 11.19.5 Tonghua Dongbao Latest Developments
- 11.20 United Laboratory
- 11.20.1 United Laboratory Company Information
- 11.20.2 United Laboratory Biosimilars and Innovative Biological Drugs Product Offered
- 11.20.3 United Laboratory Biosimilars and Innovative Biological Drugs Revenue, Gross Margin and Market Share (2019-2024)
- 11.20.4 United Laboratory Main Business Overview
- 11.20.5 United Laboratory Latest Developments
- 12 Research Findings and Conclusion
List of Tables
Table 1. Biosimilars and Innovative Biological Drugs Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ millions)
Table 2. Biosimilars and Innovative Biological Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Monoclonal Antibodies
Table 4. Major Players of Interferon
Table 5. Major Players of Insulin
Table 6. Major Players of Vaccines
Table 7. Major Players of Others
Table 8. Biosimilars and Innovative Biological Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ millions)
Table 9. Global Biosimilars and Innovative Biological Drugs Market Size by Type (2019-2024) & ($ millions)
Table 10. Global Biosimilars and Innovative Biological Drugs Market Size Market Share by Type (2019-2024)
Table 11. Biosimilars and Innovative Biological Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ millions)
Table 12. Global Biosimilars and Innovative Biological Drugs Market Size by Application (2019-2024) & ($ millions)
Table 13. Global Biosimilars and Innovative Biological Drugs Market Size Market Share by Application (2019-2024)
Table 14. Global Biosimilars and Innovative Biological Drugs Revenue by Player (2019-2024) & ($ millions)
Table 15. Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Player (2019-2024)
Table 16. Biosimilars and Innovative Biological Drugs Key Players Head office and Products Offered
Table 17. Biosimilars and Innovative Biological Drugs Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 18. New Products and Potential Entrants
Table 19. Mergers & Acquisitions, Expansion
Table 20. Global Biosimilars and Innovative Biological Drugs Market Size by Region (2019-2024) & ($ millions)
Table 21. Global Biosimilars and Innovative Biological Drugs Market Size Market Share by Region (2019-2024)
Table 22. Global Biosimilars and Innovative Biological Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 23. Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Country/Region (2019-2024)
Table 24. Americas Biosimilars and Innovative Biological Drugs Market Size by Country (2019-2024) & ($ millions)
Table 25. Americas Biosimilars and Innovative Biological Drugs Market Size Market Share by Country (2019-2024)
Table 26. Americas Biosimilars and Innovative Biological Drugs Market Size by Type (2019-2024) & ($ millions)
Table 27. Americas Biosimilars and Innovative Biological Drugs Market Size Market Share by Type (2019-2024)
Table 28. Americas Biosimilars and Innovative Biological Drugs Market Size by Application (2019-2024) & ($ millions)
Table 29. Americas Biosimilars and Innovative Biological Drugs Market Size Market Share by Application (2019-2024)
Table 30. APAC Biosimilars and Innovative Biological Drugs Market Size by Region (2019-2024) & ($ millions)
Table 31. APAC Biosimilars and Innovative Biological Drugs Market Size Market Share by Region (2019-2024)
Table 32. APAC Biosimilars and Innovative Biological Drugs Market Size by Type (2019-2024) & ($ millions)
Table 33. APAC Biosimilars and Innovative Biological Drugs Market Size by Application (2019-2024) & ($ millions)
Table 34. Europe Biosimilars and Innovative Biological Drugs Market Size by Country (2019-2024) & ($ millions)
Table 35. Europe Biosimilars and Innovative Biological Drugs Market Size Market Share by Country (2019-2024)
Table 36. Europe Biosimilars and Innovative Biological Drugs Market Size by Type (2019-2024) & ($ millions)
Table 37. Europe Biosimilars and Innovative Biological Drugs Market Size by Application (2019-2024) & ($ millions)
Table 38. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size by Region (2019-2024) & ($ millions)
Table 39. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size by Type (2019-2024) & ($ millions)
Table 40. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size by Application (2019-2024) & ($ millions)
Table 41. Key Market Drivers & Growth Opportunities of Biosimilars and Innovative Biological Drugs
Table 42. Key Market Challenges & Risks of Biosimilars and Innovative Biological Drugs
Table 43. Key Industry Trends of Biosimilars and Innovative Biological Drugs
Table 44. Global Biosimilars and Innovative Biological Drugs Market Size Forecast by Region (2025-2030) & ($ millions)
Table 45. Global Biosimilars and Innovative Biological Drugs Market Size Market Share Forecast by Region (2025-2030)
Table 46. Global Biosimilars and Innovative Biological Drugs Market Size Forecast by Type (2025-2030) & ($ millions)
Table 47. Global Biosimilars and Innovative Biological Drugs Market Size Forecast by Application (2025-2030) & ($ millions)
Table 48. Roche Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 49. Roche Biosimilars and Innovative Biological Drugs Product Offered
Table 50. Roche Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 51. Roche Main Business
Table 52. Roche Latest Developments
Table 53. Amgen Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 54. Amgen Biosimilars and Innovative Biological Drugs Product Offered
Table 55. Amgen Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 56. Amgen Main Business
Table 57. Amgen Latest Developments
Table 58. AbbVie Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 59. AbbVie Biosimilars and Innovative Biological Drugs Product Offered
Table 60. AbbVie Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 61. AbbVie Main Business
Table 62. AbbVie Latest Developments
Table 63. Sanofi Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 64. Sanofi Biosimilars and Innovative Biological Drugs Product Offered
Table 65. Sanofi Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 66. Sanofi Main Business
Table 67. Sanofi Latest Developments
Table 68. Johnson & Johnson Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 69. Johnson & Johnson Biosimilars and Innovative Biological Drugs Product Offered
Table 70. Johnson & Johnson Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 71. Johnson & Johnson Main Business
Table 72. Johnson & Johnson Latest Developments
Table 73. Pfizer Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 74. Pfizer Biosimilars and Innovative Biological Drugs Product Offered
Table 75. Pfizer Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 76. Pfizer Main Business
Table 77. Pfizer Latest Developments
Table 78. Novo Nordisk Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 79. Novo Nordisk Biosimilars and Innovative Biological Drugs Product Offered
Table 80. Novo Nordisk Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 81. Novo Nordisk Main Business
Table 82. Novo Nordisk Latest Developments
Table 83. Eli Lilly Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 84. Eli Lilly Biosimilars and Innovative Biological Drugs Product Offered
Table 85. Eli Lilly Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 86. Eli Lilly Main Business
Table 87. Eli Lilly Latest Developments
Table 88. Novartis Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 89. Novartis Biosimilars and Innovative Biological Drugs Product Offered
Table 90. Novartis Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 91. Novartis Main Business
Table 92. Novartis Latest Developments
Table 93. Merck Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 94. Merck Biosimilars and Innovative Biological Drugs Product Offered
Table 95. Merck Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 96. Merck Main Business
Table 97. Merck Latest Developments
Table 98. Biogen Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 99. Biogen Biosimilars and Innovative Biological Drugs Product Offered
Table 100. Biogen Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 101. Biogen Main Business
Table 102. Biogen Latest Developments
Table 103. Celltrion Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 104. Celltrion Biosimilars and Innovative Biological Drugs Product Offered
Table 105. Celltrion Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 106. Celltrion Main Business
Table 107. Celltrion Latest Developments
Table 108. Sobi Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 109. Sobi Biosimilars and Innovative Biological Drugs Product Offered
Table 110. Sobi Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 111. Sobi Main Business
Table 112. Sobi Latest Developments
Table 113. 3SBIO Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 114. 3SBIO Biosimilars and Innovative Biological Drugs Product Offered
Table 115. 3SBIO Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 116. 3SBIO Main Business
Table 117. 3SBIO Latest Developments
Table 118. Changchun High Tech Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 119. Changchun High Tech Biosimilars and Innovative Biological Drugs Product Offered
Table 120. Changchun High Tech Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 121. Changchun High Tech Main Business
Table 122. Changchun High Tech Latest Developments
Table 123. Kanghong Pharma Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 124. Kanghong Pharma Biosimilars and Innovative Biological Drugs Product Offered
Table 125. Kanghong Pharma Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 126. Kanghong Pharma Main Business
Table 127. Kanghong Pharma Latest Developments
Table 128. Innovent Biologics Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 129. Innovent Biologics Biosimilars and Innovative Biological Drugs Product Offered
Table 130. Innovent Biologics Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 131. Innovent Biologics Main Business
Table 132. Innovent Biologics Latest Developments
Table 133. Gan&Lee Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 134. Gan&Lee Biosimilars and Innovative Biological Drugs Product Offered
Table 135. Gan&Lee Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 136. Gan&Lee Main Business
Table 137. Gan&Lee Latest Developments
Table 138. Tonghua Dongbao Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 139. Tonghua Dongbao Biosimilars and Innovative Biological Drugs Product Offered
Table 140. Tonghua Dongbao Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 141. Tonghua Dongbao Main Business
Table 142. Tonghua Dongbao Latest Developments
Table 143. United Laboratory Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 144. United Laboratory Biosimilars and Innovative Biological Drugs Product Offered
Table 145. United Laboratory Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 146. United Laboratory Main Business
Table 147. United Laboratory Latest Developments
Table 1. Biosimilars and Innovative Biological Drugs Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ millions)
Table 2. Biosimilars and Innovative Biological Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Monoclonal Antibodies
Table 4. Major Players of Interferon
Table 5. Major Players of Insulin
Table 6. Major Players of Vaccines
Table 7. Major Players of Others
Table 8. Biosimilars and Innovative Biological Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ millions)
Table 9. Global Biosimilars and Innovative Biological Drugs Market Size by Type (2019-2024) & ($ millions)
Table 10. Global Biosimilars and Innovative Biological Drugs Market Size Market Share by Type (2019-2024)
Table 11. Biosimilars and Innovative Biological Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ millions)
Table 12. Global Biosimilars and Innovative Biological Drugs Market Size by Application (2019-2024) & ($ millions)
Table 13. Global Biosimilars and Innovative Biological Drugs Market Size Market Share by Application (2019-2024)
Table 14. Global Biosimilars and Innovative Biological Drugs Revenue by Player (2019-2024) & ($ millions)
Table 15. Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Player (2019-2024)
Table 16. Biosimilars and Innovative Biological Drugs Key Players Head office and Products Offered
Table 17. Biosimilars and Innovative Biological Drugs Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 18. New Products and Potential Entrants
Table 19. Mergers & Acquisitions, Expansion
Table 20. Global Biosimilars and Innovative Biological Drugs Market Size by Region (2019-2024) & ($ millions)
Table 21. Global Biosimilars and Innovative Biological Drugs Market Size Market Share by Region (2019-2024)
Table 22. Global Biosimilars and Innovative Biological Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 23. Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Country/Region (2019-2024)
Table 24. Americas Biosimilars and Innovative Biological Drugs Market Size by Country (2019-2024) & ($ millions)
Table 25. Americas Biosimilars and Innovative Biological Drugs Market Size Market Share by Country (2019-2024)
Table 26. Americas Biosimilars and Innovative Biological Drugs Market Size by Type (2019-2024) & ($ millions)
Table 27. Americas Biosimilars and Innovative Biological Drugs Market Size Market Share by Type (2019-2024)
Table 28. Americas Biosimilars and Innovative Biological Drugs Market Size by Application (2019-2024) & ($ millions)
Table 29. Americas Biosimilars and Innovative Biological Drugs Market Size Market Share by Application (2019-2024)
Table 30. APAC Biosimilars and Innovative Biological Drugs Market Size by Region (2019-2024) & ($ millions)
Table 31. APAC Biosimilars and Innovative Biological Drugs Market Size Market Share by Region (2019-2024)
Table 32. APAC Biosimilars and Innovative Biological Drugs Market Size by Type (2019-2024) & ($ millions)
Table 33. APAC Biosimilars and Innovative Biological Drugs Market Size by Application (2019-2024) & ($ millions)
Table 34. Europe Biosimilars and Innovative Biological Drugs Market Size by Country (2019-2024) & ($ millions)
Table 35. Europe Biosimilars and Innovative Biological Drugs Market Size Market Share by Country (2019-2024)
Table 36. Europe Biosimilars and Innovative Biological Drugs Market Size by Type (2019-2024) & ($ millions)
Table 37. Europe Biosimilars and Innovative Biological Drugs Market Size by Application (2019-2024) & ($ millions)
Table 38. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size by Region (2019-2024) & ($ millions)
Table 39. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size by Type (2019-2024) & ($ millions)
Table 40. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size by Application (2019-2024) & ($ millions)
Table 41. Key Market Drivers & Growth Opportunities of Biosimilars and Innovative Biological Drugs
Table 42. Key Market Challenges & Risks of Biosimilars and Innovative Biological Drugs
Table 43. Key Industry Trends of Biosimilars and Innovative Biological Drugs
Table 44. Global Biosimilars and Innovative Biological Drugs Market Size Forecast by Region (2025-2030) & ($ millions)
Table 45. Global Biosimilars and Innovative Biological Drugs Market Size Market Share Forecast by Region (2025-2030)
Table 46. Global Biosimilars and Innovative Biological Drugs Market Size Forecast by Type (2025-2030) & ($ millions)
Table 47. Global Biosimilars and Innovative Biological Drugs Market Size Forecast by Application (2025-2030) & ($ millions)
Table 48. Roche Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 49. Roche Biosimilars and Innovative Biological Drugs Product Offered
Table 50. Roche Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 51. Roche Main Business
Table 52. Roche Latest Developments
Table 53. Amgen Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 54. Amgen Biosimilars and Innovative Biological Drugs Product Offered
Table 55. Amgen Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 56. Amgen Main Business
Table 57. Amgen Latest Developments
Table 58. AbbVie Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 59. AbbVie Biosimilars and Innovative Biological Drugs Product Offered
Table 60. AbbVie Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 61. AbbVie Main Business
Table 62. AbbVie Latest Developments
Table 63. Sanofi Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 64. Sanofi Biosimilars and Innovative Biological Drugs Product Offered
Table 65. Sanofi Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 66. Sanofi Main Business
Table 67. Sanofi Latest Developments
Table 68. Johnson & Johnson Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 69. Johnson & Johnson Biosimilars and Innovative Biological Drugs Product Offered
Table 70. Johnson & Johnson Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 71. Johnson & Johnson Main Business
Table 72. Johnson & Johnson Latest Developments
Table 73. Pfizer Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 74. Pfizer Biosimilars and Innovative Biological Drugs Product Offered
Table 75. Pfizer Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 76. Pfizer Main Business
Table 77. Pfizer Latest Developments
Table 78. Novo Nordisk Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 79. Novo Nordisk Biosimilars and Innovative Biological Drugs Product Offered
Table 80. Novo Nordisk Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 81. Novo Nordisk Main Business
Table 82. Novo Nordisk Latest Developments
Table 83. Eli Lilly Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 84. Eli Lilly Biosimilars and Innovative Biological Drugs Product Offered
Table 85. Eli Lilly Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 86. Eli Lilly Main Business
Table 87. Eli Lilly Latest Developments
Table 88. Novartis Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 89. Novartis Biosimilars and Innovative Biological Drugs Product Offered
Table 90. Novartis Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 91. Novartis Main Business
Table 92. Novartis Latest Developments
Table 93. Merck Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 94. Merck Biosimilars and Innovative Biological Drugs Product Offered
Table 95. Merck Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 96. Merck Main Business
Table 97. Merck Latest Developments
Table 98. Biogen Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 99. Biogen Biosimilars and Innovative Biological Drugs Product Offered
Table 100. Biogen Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 101. Biogen Main Business
Table 102. Biogen Latest Developments
Table 103. Celltrion Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 104. Celltrion Biosimilars and Innovative Biological Drugs Product Offered
Table 105. Celltrion Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 106. Celltrion Main Business
Table 107. Celltrion Latest Developments
Table 108. Sobi Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 109. Sobi Biosimilars and Innovative Biological Drugs Product Offered
Table 110. Sobi Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 111. Sobi Main Business
Table 112. Sobi Latest Developments
Table 113. 3SBIO Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 114. 3SBIO Biosimilars and Innovative Biological Drugs Product Offered
Table 115. 3SBIO Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 116. 3SBIO Main Business
Table 117. 3SBIO Latest Developments
Table 118. Changchun High Tech Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 119. Changchun High Tech Biosimilars and Innovative Biological Drugs Product Offered
Table 120. Changchun High Tech Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 121. Changchun High Tech Main Business
Table 122. Changchun High Tech Latest Developments
Table 123. Kanghong Pharma Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 124. Kanghong Pharma Biosimilars and Innovative Biological Drugs Product Offered
Table 125. Kanghong Pharma Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 126. Kanghong Pharma Main Business
Table 127. Kanghong Pharma Latest Developments
Table 128. Innovent Biologics Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 129. Innovent Biologics Biosimilars and Innovative Biological Drugs Product Offered
Table 130. Innovent Biologics Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 131. Innovent Biologics Main Business
Table 132. Innovent Biologics Latest Developments
Table 133. Gan&Lee Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 134. Gan&Lee Biosimilars and Innovative Biological Drugs Product Offered
Table 135. Gan&Lee Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 136. Gan&Lee Main Business
Table 137. Gan&Lee Latest Developments
Table 138. Tonghua Dongbao Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 139. Tonghua Dongbao Biosimilars and Innovative Biological Drugs Product Offered
Table 140. Tonghua Dongbao Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 141. Tonghua Dongbao Main Business
Table 142. Tonghua Dongbao Latest Developments
Table 143. United Laboratory Details, Company Type, Biosimilars and Innovative Biological Drugs Area Served and Its Competitors
Table 144. United Laboratory Biosimilars and Innovative Biological Drugs Product Offered
Table 145. United Laboratory Biosimilars and Innovative Biological Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 146. United Laboratory Main Business
Table 147. United Laboratory Latest Developments
List of Figures
Figure 1. Biosimilars and Innovative Biological Drugs Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Biosimilars and Innovative Biological Drugs Market Size Growth Rate 2019-2030 ($ millions)
Figure 6. Biosimilars and Innovative Biological Drugs Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Biosimilars and Innovative Biological Drugs Sales Market Share by Country/Region (2023)
Figure 8. Biosimilars and Innovative Biological Drugs Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Biosimilars and Innovative Biological Drugs Market Size Market Share by Type in 2023
Figure 10. Biosimilars and Innovative Biological Drugs in Hospital
Figure 11. Global Biosimilars and Innovative Biological Drugs Market: Hospital (2019-2024) & ($ millions)
Figure 12. Biosimilars and Innovative Biological Drugs in Retail Pharmacy
Figure 13. Global Biosimilars and Innovative Biological Drugs Market: Retail Pharmacy (2019-2024) & ($ millions)
Figure 14. Biosimilars and Innovative Biological Drugs in Other
Figure 15. Global Biosimilars and Innovative Biological Drugs Market: Other (2019-2024) & ($ millions)
Figure 16. Global Biosimilars and Innovative Biological Drugs Market Size Market Share by Application in 2023
Figure 17. Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Player in 2023
Figure 18. Global Biosimilars and Innovative Biological Drugs Market Size Market Share by Region (2019-2024)
Figure 19. Americas Biosimilars and Innovative Biological Drugs Market Size 2019-2024 ($ millions)
Figure 20. APAC Biosimilars and Innovative Biological Drugs Market Size 2019-2024 ($ millions)
Figure 21. Europe Biosimilars and Innovative Biological Drugs Market Size 2019-2024 ($ millions)
Figure 22. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size 2019-2024 ($ millions)
Figure 23. Americas Biosimilars and Innovative Biological Drugs Value Market Share by Country in 2023
Figure 24. United States Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 25. Canada Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 26. Mexico Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 27. Brazil Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 28. APAC Biosimilars and Innovative Biological Drugs Market Size Market Share by Region in 2023
Figure 29. APAC Biosimilars and Innovative Biological Drugs Market Size Market Share by Type (2019-2024)
Figure 30. APAC Biosimilars and Innovative Biological Drugs Market Size Market Share by Application (2019-2024)
Figure 31. China Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 32. Japan Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 33. South Korea Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 34. Southeast Asia Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 35. India Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 36. Australia Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 37. Europe Biosimilars and Innovative Biological Drugs Market Size Market Share by Country in 2023
Figure 38. Europe Biosimilars and Innovative Biological Drugs Market Size Market Share by Type (2019-2024)
Figure 39. Europe Biosimilars and Innovative Biological Drugs Market Size Market Share by Application (2019-2024)
Figure 40. Germany Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 41. France Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 42. UK Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 43. Italy Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 44. Russia Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 45. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size Market Share by Region (2019-2024)
Figure 46. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size Market Share by Type (2019-2024)
Figure 47. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size Market Share by Application (2019-2024)
Figure 48. Egypt Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 49. South Africa Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 50. Israel Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 51. Turkey Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 52. GCC Countries Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 53. Americas Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 54. APAC Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 55. Europe Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 56. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 57. United States Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 58. Canada Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 59. Mexico Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 60. Brazil Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 61. China Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 62. Japan Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 63. Korea Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 64. Southeast Asia Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 65. India Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 66. Australia Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 67. Germany Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 68. France Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 69. UK Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 70. Italy Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 71. Russia Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 72. Egypt Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 73. South Africa Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 74. Israel Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 75. Turkey Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 76. GCC Countries Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 77. Global Biosimilars and Innovative Biological Drugs Market Size Market Share Forecast by Type (2025-2030)
Figure 78. Global Biosimilars and Innovative Biological Drugs Market Size Market Share Forecast by Application (2025-2030)
"
Figure 1. Biosimilars and Innovative Biological Drugs Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Biosimilars and Innovative Biological Drugs Market Size Growth Rate 2019-2030 ($ millions)
Figure 6. Biosimilars and Innovative Biological Drugs Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Biosimilars and Innovative Biological Drugs Sales Market Share by Country/Region (2023)
Figure 8. Biosimilars and Innovative Biological Drugs Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Biosimilars and Innovative Biological Drugs Market Size Market Share by Type in 2023
Figure 10. Biosimilars and Innovative Biological Drugs in Hospital
Figure 11. Global Biosimilars and Innovative Biological Drugs Market: Hospital (2019-2024) & ($ millions)
Figure 12. Biosimilars and Innovative Biological Drugs in Retail Pharmacy
Figure 13. Global Biosimilars and Innovative Biological Drugs Market: Retail Pharmacy (2019-2024) & ($ millions)
Figure 14. Biosimilars and Innovative Biological Drugs in Other
Figure 15. Global Biosimilars and Innovative Biological Drugs Market: Other (2019-2024) & ($ millions)
Figure 16. Global Biosimilars and Innovative Biological Drugs Market Size Market Share by Application in 2023
Figure 17. Global Biosimilars and Innovative Biological Drugs Revenue Market Share by Player in 2023
Figure 18. Global Biosimilars and Innovative Biological Drugs Market Size Market Share by Region (2019-2024)
Figure 19. Americas Biosimilars and Innovative Biological Drugs Market Size 2019-2024 ($ millions)
Figure 20. APAC Biosimilars and Innovative Biological Drugs Market Size 2019-2024 ($ millions)
Figure 21. Europe Biosimilars and Innovative Biological Drugs Market Size 2019-2024 ($ millions)
Figure 22. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size 2019-2024 ($ millions)
Figure 23. Americas Biosimilars and Innovative Biological Drugs Value Market Share by Country in 2023
Figure 24. United States Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 25. Canada Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 26. Mexico Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 27. Brazil Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 28. APAC Biosimilars and Innovative Biological Drugs Market Size Market Share by Region in 2023
Figure 29. APAC Biosimilars and Innovative Biological Drugs Market Size Market Share by Type (2019-2024)
Figure 30. APAC Biosimilars and Innovative Biological Drugs Market Size Market Share by Application (2019-2024)
Figure 31. China Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 32. Japan Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 33. South Korea Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 34. Southeast Asia Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 35. India Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 36. Australia Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 37. Europe Biosimilars and Innovative Biological Drugs Market Size Market Share by Country in 2023
Figure 38. Europe Biosimilars and Innovative Biological Drugs Market Size Market Share by Type (2019-2024)
Figure 39. Europe Biosimilars and Innovative Biological Drugs Market Size Market Share by Application (2019-2024)
Figure 40. Germany Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 41. France Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 42. UK Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 43. Italy Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 44. Russia Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 45. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size Market Share by Region (2019-2024)
Figure 46. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size Market Share by Type (2019-2024)
Figure 47. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size Market Share by Application (2019-2024)
Figure 48. Egypt Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 49. South Africa Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 50. Israel Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 51. Turkey Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 52. GCC Countries Biosimilars and Innovative Biological Drugs Market Size Growth 2019-2024 ($ millions)
Figure 53. Americas Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 54. APAC Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 55. Europe Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 56. Middle East & Africa Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 57. United States Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 58. Canada Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 59. Mexico Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 60. Brazil Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 61. China Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 62. Japan Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 63. Korea Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 64. Southeast Asia Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 65. India Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 66. Australia Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 67. Germany Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 68. France Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 69. UK Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 70. Italy Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 71. Russia Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 72. Egypt Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 73. South Africa Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 74. Israel Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 75. Turkey Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 76. GCC Countries Biosimilars and Innovative Biological Drugs Market Size 2025-2030 ($ millions)
Figure 77. Global Biosimilars and Innovative Biological Drugs Market Size Market Share Forecast by Type (2025-2030)
Figure 78. Global Biosimilars and Innovative Biological Drugs Market Size Market Share Forecast by Application (2025-2030)
"
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Trusted Partners
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (09 May, 2026)
- Notify To Team (09 May, 2026)
- Report updation (10 May, 2026)
- Report Quality Check (10 May, 2026)
- Report Dispatch (11 May, 2026)
- Hard Copy
Recently Viewed Products
Global Biosimilars and Innovative Biological Drugs Market Outlook , 2030
We are friendly and approachable, give us a call.